Evidence map›Paper›PMID 25790093›Full record

ArticleCell cycle (Georgetown, Tex.)2015

TAp63gamma is required for the late stages of myogenesis.

S Cefalù, A M Lena, B Vojtesek, A Musarò, A Rossi, G Melino, E Candi

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Splicing Factor PTBP1 RepressesCancer research communications · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. p63-related signaling at a glance.Journal of cell science · 2020
    Review
  11. Article
  12. Master regulatory role of p63 in epidermal development and disease.Cellular and molecular life sciences : CMLS · 2018
    Review
  13. Article
  14. Frontiers in physiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

S Cefalùa Istututo Dermopatico dell'Immacolata ; IDI-IRCCS ; Rome , Italy.
A M Lena
B Vojtesek
A Musarò
A Rossi
G Melino
E Candi
University of Rome Tor Vergata · ITIstituto Dermopatico dell'Immacolata · ITIstituto Pasteur · ITMasaryk Memorial Cancer Institute · CZ

Funding

Medical Research Council MC_U132670600Telethon GGP13013
6 · The paper itself

Abstract

p53 family members, p63 and p73, play a role in controlling early stage of myogenic differentiation. We demonstrated that TAp63gamma, unlike the other p53 family members, is markedly up-regulated during myogenic differentiation in murine C2C7 cell line. We also found that myotubes formation was inhibited upon TAp63gamma knock-down, as also indicated by atrophyic myotubes and reduction of myoblasts fusion index. Analysis of TAp63gamma-dependend transcripts identified several target genes involved in skeletal muscle contractility energy metabolism, myogenesis and skeletal muscle autocrine signaling. These results indicate that TAp63gamma is a late marker of myogenic differentiation and, by controlling different sub-sets of target genes, it possibly contributes to muscle growth, remodeling, functional differentiation and tissue homeostasis.

Indexed as

Muscle DevelopmentAnimalsCell DifferentiationCell LineGene Expression Regulation, DevelopmentalGene Knockdown TechniquesMiceMuscle Fibers, SkeletalMyoblastsOrgan SpecificityPhosphoproteinsReproducibility of ResultsTrans-ActivatorsPhosphoproteinsTrans-ActivatorsTrp63 protein, mousedifferentiationMHC, myosin heavy chainMRFs, myogenic regulatory factorsmuscle contractilitymyogenesisp53p63Rb, retinoblastoma protein

Identifiers

PMID25790093
PMCPMC4615066
OpenAlexW1978521643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.